Overview
John H. Alexander, MD, MHS is a cardiologist and Professor of Medicine in the Department of Medicine, Division of Cardiology at Duke University School of Medicine, as well as the Vice Chief, Clinical Research in the Division of Cardiology. He is the Director of Cardiovascular Research at the Duke Clinical Research Institute where he oversees a large group of clinical research faculty and a broad portfolio of cardiovascular clinical trials and observational clinical research programs. He is a member of the American Society of Clinical Investigation.
Dr. Alexander’s clinical interests are in acute and general cardiovascular disease, valvular heart disease, and echocardiology. His research is focused on the translation of novel therapeutic concepts into clinical data through clinical trials, specifically on the therapeutics of acute coronary syndromes, chronic coronary artery disease, and cardiac surgery and on novel methodological approaches to clinical trials. He was on the Executive Committee of the ARISTOTLE trial of apixaban in patients with atrial fibrillation and was the Principal Investigator of the APPRAISE-2 trial of apixaban in patients with acute coronary syndromes.
Dr. Alexander has published extensively and has served as the principal investigator of numerous multicenter clinical trials. He currently serves as the co-chair of the Clinical Trial Transformation Initiative (CTTI).
Current Appointments & Affiliations
Recent Publications
Transfusion-related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the MINT trial.
Journal Article Transfusion · November 26, 2025 BACKGROUND: The aim of this analysis was to quantify and compare the frequency of transfusion-related adverse events (TRAE) in adult patients with myocardial infarction transfused with a restrictive versus liberal transfusion strategy from the Myocardial I ... Full text Link to item CiteCorrection to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
Journal Article Circulation · November 11, 2025 Full text Link to item CiteFactor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism.
Journal Article Nat Rev Cardiol · November 2025 Therapeutic anticoagulation is essential to prevent and treat venous and arterial thromboembolism. The available agents target coagulation factors involved in thrombus formation but are associated with an increased risk of bleeding. Factor XI plays a minor ... Full text Link to item CiteRecent Grants
Increasing the Quality and Efficiency of Clinical Trials (U18)
ResearchPrincipal Investigator · Awarded by Food and Drug Administration · 2014 - 2029Stimulating Access to Research in Residency (StARR) - NHLBI
Inst. Training Prgm or CMEPreceptor · Awarded by National Heart, Lung, and Blood Institute · 2018 - 2028RECHARGE Hybrid: Revascularization of Underrepresented Groups with minimally-invasive CABG plus PCI
ResearchCo-Mentor · Awarded by Thoracic Surgery Foundation for Research and Education · 2025 - 2027View All Grants